Drugs / XEN-101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06417697 | May → Sep 2024 | obesity disorder | Xeno Biosciences | Terminated | No outcome recorded |
| Phase 1 | NCT05667129 | Dec 2022 → May 2023 | — | Xeno Biosciences | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XEN-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05667129 ↗ |